• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?
RESEARCH UPDATE

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

September 1, 2013
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

Section editor, Glen Spielmans, PhD

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.

Subject:
Psychosis

Short Description:

Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

Background:

What’s the optimal treatment for a first episode of psychosis? Few would argue against antipsychotic treatment, but what happens when the patient achieves remission? Is it best to continue medication indefinitely, or can the antipsychotic be reduced or discontinued altogether?

One hundred and twenty eight patients who had a first episode of psychosis (FEP) in 2001–2002 were successfully treated with antipsychotics. Of these, half were randomized to continue medications (MT), and the other half to reduce their doses (DR) after six months of remission, tapering off of medications if possible. Most (N=103) were identified seven years later for a follow-up evaluation. Of these, half (N=52) had been randomized to the symptom-guided dose reduction (DR) strategy.

At the seven-year mark, investigators evaluated the patients for both symptomatic and functional recovery. Symptoms were measured by the Positive and Negative Syndrome Scale (PANSS); function was measured by the Groningen Social Disability Scale (GSDS). Rates of symptomatic remission were essentially identical between the two groups (MT, 66.7%; DR, 69.2%) while functional remission was significantly higher in those randomly assigned to the dose-reduction group (MT, 19.6%; DR, 46.2%). “Recovery,” defined as both symptomatic and functional remission, was also higher in the DR group (MT, 17.6%; DR 40.2%).

Some patients in the MT group had discontinued antipsychotics or reduced their doses to amounts comparable to those in the DR group. When the investigators looked at all the patients who had either discontinued or reduced their doses to subtherapeutic levels (N=34), symptomatic remission was found in 85.3% (vs. 59.4% of those who had not, N=69) and functional remission in 55.9% (vs. 21.7%). These patients were also more likely to have recovered (52.9% vs. 17.4%).

When investigators looked at relapse rates over the seven-year trial, they found, perhaps not surprisingly, higher relapse rates in the DR group over the first three years. But they observed roughly equivalent rates thereafter. They argue that the key difference between the two groups after seven years is neither in relapse rate nor in level of symptoms, but in the degree of functional recovery, and that this measure requires further investigation, as it represents a better measure of patients’ overall status (Wunderlink L et al, JAMA Psychiatry 2013, online ahead of print).

TCPR’s TAKE: Few would argue that first-episode psychosis requires treatment, but this study suggests that maintenance of antipsychotics after remission may not be necessary. After the decrease or discontinuation of medications, symptoms do not become worse. In fact, function may actually improve over a seven-year period. The reasons are unclear, but they argue for a greater focus on functional improvement and psychosocial interventions than on maintenance antipsychotic medication.

General Psychiatry Research Update
KEYWORDS antipsychotics research_updates
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    L-Methylfolate May Offer Modest Boost to Antidepressants

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2013
    SUBSCRIBE NOW
    Table Of Contents
    Antipsychotics and Anticonvulsants for Anxiety Disorders
    Table - FDA Approved Medications for Anxiety
    Anxiety Disorders in DSM-5 and Beyond
    Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?
    Fetzima Approved for Depression
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.